Anti-Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases.
Identifieur interne : 001789 ( Main/Exploration ); précédent : 001788; suivant : 001790Anti-Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases.
Auteurs : Zhe Li [Belgique] ; Séverine Vermeire ; Dominique Bullens ; Marc Ferrante ; Kristel Van Steen ; Maja Noman ; Xavier Bossuyt ; Paul Rutgeerts ; Jan L. Ceuppens ; Gert Van AsscheSource :
- Inflammatory bowel diseases [ 1536-4844 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Agents gastro-intestinaux (pharmacologie), Agents gastro-intestinaux (sang), Antigènes CD19 (sang), Antigènes CD40 (effets des médicaments et des substances chimiques), Antigènes CD40 (sang), Antigènes CD5 (sang), Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs), Femelle (MeSH), Humains (MeSH), Infliximab (pharmacologie), Infliximab (sang), Lymphocytes B (effets des médicaments et des substances chimiques), Maladies inflammatoires intestinales (sang), Maladies inflammatoires intestinales (traitement médicamenteux), Mâle (MeSH), Protéine C-réactive (effets des médicaments et des substances chimiques), Régulation positive (MeSH), Sous-populations de lymphocytes B (cytologie), Sous-populations de lymphocytes B (effets des médicaments et des substances chimiques), Études cas-témoins (MeSH).
- MESH :
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- cytologie : Sous-populations de lymphocytes B.
- effets des médicaments et des substances chimiques : Antigènes CD40, Lymphocytes B, Protéine C-réactive, Sous-populations de lymphocytes B.
- pharmacologie : Agents gastro-intestinaux, Infliximab.
- sang : Agents gastro-intestinaux, Antigènes CD19, Antigènes CD40, Antigènes CD5, Infliximab, Maladies inflammatoires intestinales.
- traitement médicamenteux : Maladies inflammatoires intestinales.
- Adulte, Femelle, Humains, Mâle, Régulation positive, Études cas-témoins.
English descriptors
- KwdEn :
- Adult (MeSH), Antigens, CD19 (blood), B-Lymphocyte Subsets (cytology), B-Lymphocyte Subsets (drug effects), B-Lymphocytes (drug effects), C-Reactive Protein (drug effects), CD40 Antigens (blood), CD40 Antigens (drug effects), CD5 Antigens (blood), Case-Control Studies (MeSH), Female (MeSH), Gastrointestinal Agents (blood), Gastrointestinal Agents (pharmacology), Humans (MeSH), Inflammatory Bowel Diseases (blood), Inflammatory Bowel Diseases (drug therapy), Infliximab (blood), Infliximab (pharmacology), Male (MeSH), Tumor Necrosis Factor-alpha (antagonists & inhibitors), Up-Regulation (MeSH).
- MESH :
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , blood : Antigens, CD19, CD40 Antigens, CD5 Antigens, Gastrointestinal Agents, Infliximab.
- blood : Inflammatory Bowel Diseases.
- cytology : B-Lymphocyte Subsets.
- drug effects : B-Lymphocyte Subsets, B-Lymphocytes, C-Reactive Protein, CD40 Antigens.
- drug therapy : Inflammatory Bowel Diseases.
- chemical , pharmacology : Gastrointestinal Agents, Infliximab.
- Adult, Case-Control Studies, Female, Humans, Male, Up-Regulation.
Abstract
BACKGROUND
Anti-tumor necrosis factor (TNF) therapy has become a standard therapy for severe inflammatory bowel diseases (IBD), but its effect on B lymphocytes is largely unexplored. In this study we investigated peripheral blood B cells, B-cell subsets, and CD40 expression in patients with IBD before and during anti-TNF therapy with infliximab (IFX).
METHODS
Blood was taken from healthy controls (n = 52) and patients with active IBD before (n = 46) and/or during anti-TNF therapy (n = 55). B-cell markers were detected by immunofluorescent staining and FACS analysis. Patients were classified as responders or nonresponders to anti-TNF therapy.
RESULTS
We found a numerical deficiency of circulating CD19 B cells, a lower activation state (CD40 expression) and lower proportions of CD5 B cells and IgMIgDCD27 preswitched memory cells among B cells in active patients with IBD before IFX therapy compared with healthy controls. IFX treatment increased CD19 B-cell numbers as well as the proportions of named B-cell subsets in responders but not in nonresponders. IFX more effectively upregulated CD40 expression in responders than in nonresponders. Restoration of B cells correlated with the biological response to therapy (C-reactive protein). Trough serum levels of IFX correlated with the number of B cells during therapy.
CONCLUSIONS
A lower number of circulating B cells, a low CD40 expression, and a decrease in the proportion of CD5 and in the preswitched memory subset characterize active IBD. Restoration of these abnormalities correlates with the clinical response to anti-TNF therapy. The mechanism for this effect on B cells should be further explored.
DOI: 10.1097/MIB.0000000000000554
PubMed: 26383913
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases.</title><author><name sortKey="Li, Zhe" sort="Li, Zhe" uniqKey="Li Z" first="Zhe" last="Li">Zhe Li</name><affiliation wicri:level="1"><nlm:affiliation>*Clinical Immunology Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium; †Division of Gastroenterology, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium; ‡Laboratory of Pediatric Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium; §Department of Bioinformatics-Statistical Genetics, Université of Liège, Liège, Belgium; and ‖Experimental Laboratory Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>*Clinical Immunology Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium; †Division of Gastroenterology, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium; ‡Laboratory of Pediatric Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium; §Department of Bioinformatics-Statistical Genetics, Université of Liège, Liège, Belgium; and ‖Experimental Laboratory Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Vermeire, Severine" sort="Vermeire, Severine" uniqKey="Vermeire S" first="Séverine" last="Vermeire">Séverine Vermeire</name></author><author><name sortKey="Bullens, Dominique" sort="Bullens, Dominique" uniqKey="Bullens D" first="Dominique" last="Bullens">Dominique Bullens</name></author><author><name sortKey="Ferrante, Marc" sort="Ferrante, Marc" uniqKey="Ferrante M" first="Marc" last="Ferrante">Marc Ferrante</name></author><author><name sortKey="Van Steen, Kristel" sort="Van Steen, Kristel" uniqKey="Van Steen K" first="Kristel" last="Van Steen">Kristel Van Steen</name></author><author><name sortKey="Noman, Maja" sort="Noman, Maja" uniqKey="Noman M" first="Maja" last="Noman">Maja Noman</name></author><author><name sortKey="Bossuyt, Xavier" sort="Bossuyt, Xavier" uniqKey="Bossuyt X" first="Xavier" last="Bossuyt">Xavier Bossuyt</name></author><author><name sortKey="Rutgeerts, Paul" sort="Rutgeerts, Paul" uniqKey="Rutgeerts P" first="Paul" last="Rutgeerts">Paul Rutgeerts</name></author><author><name sortKey="Ceuppens, Jan L" sort="Ceuppens, Jan L" uniqKey="Ceuppens J" first="Jan L" last="Ceuppens">Jan L. Ceuppens</name></author><author><name sortKey="Van Assche, Gert" sort="Van Assche, Gert" uniqKey="Van Assche G" first="Gert" last="Van Assche">Gert Van Assche</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26383913</idno><idno type="pmid">26383913</idno><idno type="doi">10.1097/MIB.0000000000000554</idno><idno type="wicri:Area/Main/Corpus">001393</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001393</idno><idno type="wicri:Area/Main/Curation">001393</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001393</idno><idno type="wicri:Area/Main/Exploration">001393</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Anti-Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases.</title><author><name sortKey="Li, Zhe" sort="Li, Zhe" uniqKey="Li Z" first="Zhe" last="Li">Zhe Li</name><affiliation wicri:level="1"><nlm:affiliation>*Clinical Immunology Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium; †Division of Gastroenterology, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium; ‡Laboratory of Pediatric Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium; §Department of Bioinformatics-Statistical Genetics, Université of Liège, Liège, Belgium; and ‖Experimental Laboratory Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>*Clinical Immunology Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium; †Division of Gastroenterology, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium; ‡Laboratory of Pediatric Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium; §Department of Bioinformatics-Statistical Genetics, Université of Liège, Liège, Belgium; and ‖Experimental Laboratory Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Vermeire, Severine" sort="Vermeire, Severine" uniqKey="Vermeire S" first="Séverine" last="Vermeire">Séverine Vermeire</name></author><author><name sortKey="Bullens, Dominique" sort="Bullens, Dominique" uniqKey="Bullens D" first="Dominique" last="Bullens">Dominique Bullens</name></author><author><name sortKey="Ferrante, Marc" sort="Ferrante, Marc" uniqKey="Ferrante M" first="Marc" last="Ferrante">Marc Ferrante</name></author><author><name sortKey="Van Steen, Kristel" sort="Van Steen, Kristel" uniqKey="Van Steen K" first="Kristel" last="Van Steen">Kristel Van Steen</name></author><author><name sortKey="Noman, Maja" sort="Noman, Maja" uniqKey="Noman M" first="Maja" last="Noman">Maja Noman</name></author><author><name sortKey="Bossuyt, Xavier" sort="Bossuyt, Xavier" uniqKey="Bossuyt X" first="Xavier" last="Bossuyt">Xavier Bossuyt</name></author><author><name sortKey="Rutgeerts, Paul" sort="Rutgeerts, Paul" uniqKey="Rutgeerts P" first="Paul" last="Rutgeerts">Paul Rutgeerts</name></author><author><name sortKey="Ceuppens, Jan L" sort="Ceuppens, Jan L" uniqKey="Ceuppens J" first="Jan L" last="Ceuppens">Jan L. Ceuppens</name></author><author><name sortKey="Van Assche, Gert" sort="Van Assche, Gert" uniqKey="Van Assche G" first="Gert" last="Van Assche">Gert Van Assche</name></author></analytic><series><title level="j">Inflammatory bowel diseases</title><idno type="eISSN">1536-4844</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Antigens, CD19 (blood)</term><term>B-Lymphocyte Subsets (cytology)</term><term>B-Lymphocyte Subsets (drug effects)</term><term>B-Lymphocytes (drug effects)</term><term>C-Reactive Protein (drug effects)</term><term>CD40 Antigens (blood)</term><term>CD40 Antigens (drug effects)</term><term>CD5 Antigens (blood)</term><term>Case-Control Studies (MeSH)</term><term>Female (MeSH)</term><term>Gastrointestinal Agents (blood)</term><term>Gastrointestinal Agents (pharmacology)</term><term>Humans (MeSH)</term><term>Inflammatory Bowel Diseases (blood)</term><term>Inflammatory Bowel Diseases (drug therapy)</term><term>Infliximab (blood)</term><term>Infliximab (pharmacology)</term><term>Male (MeSH)</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term><term>Up-Regulation (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Agents gastro-intestinaux (pharmacologie)</term><term>Agents gastro-intestinaux (sang)</term><term>Antigènes CD19 (sang)</term><term>Antigènes CD40 (effets des médicaments et des substances chimiques)</term><term>Antigènes CD40 (sang)</term><term>Antigènes CD5 (sang)</term><term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Infliximab (pharmacologie)</term><term>Infliximab (sang)</term><term>Lymphocytes B (effets des médicaments et des substances chimiques)</term><term>Maladies inflammatoires intestinales (sang)</term><term>Maladies inflammatoires intestinales (traitement médicamenteux)</term><term>Mâle (MeSH)</term><term>Protéine C-réactive (effets des médicaments et des substances chimiques)</term><term>Régulation positive (MeSH)</term><term>Sous-populations de lymphocytes B (cytologie)</term><term>Sous-populations de lymphocytes B (effets des médicaments et des substances chimiques)</term><term>Études cas-témoins (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antigens, CD19</term><term>CD40 Antigens</term><term>CD5 Antigens</term><term>Gastrointestinal Agents</term><term>Infliximab</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Inflammatory Bowel Diseases</term></keywords><keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Sous-populations de lymphocytes B</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>B-Lymphocyte Subsets</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>B-Lymphocyte Subsets</term><term>B-Lymphocytes</term><term>C-Reactive Protein</term><term>CD40 Antigens</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Inflammatory Bowel Diseases</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Antigènes CD40</term><term>Lymphocytes B</term><term>Protéine C-réactive</term><term>Sous-populations de lymphocytes B</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents gastro-intestinaux</term><term>Infliximab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Gastrointestinal Agents</term><term>Infliximab</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Agents gastro-intestinaux</term><term>Antigènes CD19</term><term>Antigènes CD40</term><term>Antigènes CD5</term><term>Infliximab</term><term>Maladies inflammatoires intestinales</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies inflammatoires intestinales</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Case-Control Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Up-Regulation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Régulation positive</term><term>Études cas-témoins</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Anti-tumor necrosis factor (TNF) therapy has become a standard therapy for severe inflammatory bowel diseases (IBD), but its effect on B lymphocytes is largely unexplored. In this study we investigated peripheral blood B cells, B-cell subsets, and CD40 expression in patients with IBD before and during anti-TNF therapy with infliximab (IFX).</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Blood was taken from healthy controls (n = 52) and patients with active IBD before (n = 46) and/or during anti-TNF therapy (n = 55). B-cell markers were detected by immunofluorescent staining and FACS analysis. Patients were classified as responders or nonresponders to anti-TNF therapy.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>We found a numerical deficiency of circulating CD19 B cells, a lower activation state (CD40 expression) and lower proportions of CD5 B cells and IgMIgDCD27 preswitched memory cells among B cells in active patients with IBD before IFX therapy compared with healthy controls. IFX treatment increased CD19 B-cell numbers as well as the proportions of named B-cell subsets in responders but not in nonresponders. IFX more effectively upregulated CD40 expression in responders than in nonresponders. Restoration of B cells correlated with the biological response to therapy (C-reactive protein). Trough serum levels of IFX correlated with the number of B cells during therapy.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>A lower number of circulating B cells, a low CD40 expression, and a decrease in the proportion of CD5 and in the preswitched memory subset characterize active IBD. Restoration of these abnormalities correlates with the clinical response to anti-TNF therapy. The mechanism for this effect on B cells should be further explored.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26383913</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2018</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-4844</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Inflammatory bowel diseases</Title><ISOAbbreviation>Inflamm Bowel Dis</ISOAbbreviation></Journal><ArticleTitle>Anti-Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases.</ArticleTitle><Pagination><MedlinePgn>2787-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MIB.0000000000000554</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Anti-tumor necrosis factor (TNF) therapy has become a standard therapy for severe inflammatory bowel diseases (IBD), but its effect on B lymphocytes is largely unexplored. In this study we investigated peripheral blood B cells, B-cell subsets, and CD40 expression in patients with IBD before and during anti-TNF therapy with infliximab (IFX).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Blood was taken from healthy controls (n = 52) and patients with active IBD before (n = 46) and/or during anti-TNF therapy (n = 55). B-cell markers were detected by immunofluorescent staining and FACS analysis. Patients were classified as responders or nonresponders to anti-TNF therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found a numerical deficiency of circulating CD19 B cells, a lower activation state (CD40 expression) and lower proportions of CD5 B cells and IgMIgDCD27 preswitched memory cells among B cells in active patients with IBD before IFX therapy compared with healthy controls. IFX treatment increased CD19 B-cell numbers as well as the proportions of named B-cell subsets in responders but not in nonresponders. IFX more effectively upregulated CD40 expression in responders than in nonresponders. Restoration of B cells correlated with the biological response to therapy (C-reactive protein). Trough serum levels of IFX correlated with the number of B cells during therapy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A lower number of circulating B cells, a low CD40 expression, and a decrease in the proportion of CD5 and in the preswitched memory subset characterize active IBD. Restoration of these abnormalities correlates with the clinical response to anti-TNF therapy. The mechanism for this effect on B cells should be further explored.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>*Clinical Immunology Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium; †Division of Gastroenterology, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium; ‡Laboratory of Pediatric Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium; §Department of Bioinformatics-Statistical Genetics, Université of Liège, Liège, Belgium; and ‖Experimental Laboratory Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vermeire</LastName><ForeName>Séverine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bullens</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ferrante</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Van Steen</LastName><ForeName>Kristel</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Noman</LastName><ForeName>Maja</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bossuyt</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Rutgeerts</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ceuppens</LastName><ForeName>Jan L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Van Assche</LastName><ForeName>Gert</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Inflamm Bowel Dis</MedlineTA><NlmUniqueID>9508162</NlmUniqueID><ISSNLinking>1078-0998</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018941">Antigens, CD19</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019013">CD40 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018956">CD5 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005765">Gastrointestinal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>B72HH48FLU</RegistryNumber><NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018941" MajorTopicYN="N">Antigens, CD19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016175" MajorTopicYN="N">B-Lymphocyte Subsets</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019013" MajorTopicYN="N">CD40 Antigens</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018956" MajorTopicYN="N">CD5 Antigens</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005765" MajorTopicYN="N">Gastrointestinal Agents</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26383913</ArticleId><ArticleId IdType="doi">10.1097/MIB.0000000000000554</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Belgique</li></country></list><tree><noCountry><name sortKey="Bossuyt, Xavier" sort="Bossuyt, Xavier" uniqKey="Bossuyt X" first="Xavier" last="Bossuyt">Xavier Bossuyt</name><name sortKey="Bullens, Dominique" sort="Bullens, Dominique" uniqKey="Bullens D" first="Dominique" last="Bullens">Dominique Bullens</name><name sortKey="Ceuppens, Jan L" sort="Ceuppens, Jan L" uniqKey="Ceuppens J" first="Jan L" last="Ceuppens">Jan L. Ceuppens</name><name sortKey="Ferrante, Marc" sort="Ferrante, Marc" uniqKey="Ferrante M" first="Marc" last="Ferrante">Marc Ferrante</name><name sortKey="Noman, Maja" sort="Noman, Maja" uniqKey="Noman M" first="Maja" last="Noman">Maja Noman</name><name sortKey="Rutgeerts, Paul" sort="Rutgeerts, Paul" uniqKey="Rutgeerts P" first="Paul" last="Rutgeerts">Paul Rutgeerts</name><name sortKey="Van Assche, Gert" sort="Van Assche, Gert" uniqKey="Van Assche G" first="Gert" last="Van Assche">Gert Van Assche</name><name sortKey="Van Steen, Kristel" sort="Van Steen, Kristel" uniqKey="Van Steen K" first="Kristel" last="Van Steen">Kristel Van Steen</name><name sortKey="Vermeire, Severine" sort="Vermeire, Severine" uniqKey="Vermeire S" first="Séverine" last="Vermeire">Séverine Vermeire</name></noCountry><country name="Belgique"><noRegion><name sortKey="Li, Zhe" sort="Li, Zhe" uniqKey="Li Z" first="Zhe" last="Li">Zhe Li</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001789 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001789 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= BiopestPeptidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26383913
|texte= Anti-Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26383913" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a BiopestPeptidV1
| This area was generated with Dilib version V0.6.38. |  |